

**Supplementary Table 2.** Insurance coverage criteria for obesity metabolic surgery in Korea and Japan

	Korea	Japan
Indication	<p>A. If 1)–3) are satisfied</p> <p>1) Indication</p> <p>① BMI <math>\geq 35</math> kg/m<sup>2</sup> or</p> <p>② BMI <math>\geq 30</math> kg/m<sup>2</sup> accompanied by complications (hypertension, hypoventilation, sleep apnea, joint disease, non-alcoholic fatty liver disease, gastroesophageal reflux disease, type 2 diabetes mellitus, hyperlipidemia, asthma, cardiomyopathy, coronary artery disease, polycystic ovary syndrome, pseudotumor cerebri)</p> <p>③ If sleeve gastrectomy and non-resectable Roux-en-Y gastric bypass are performed on type 2 diabetes mellitus patients with <math>27.5 \leq \text{BMI} &lt; 30</math> kg/m<sup>2</sup> who cannot control their blood sugar levels with existing internal medicine treatment and lifestyle improvement (in this case, the surgical fee and treatment material cost are applied at a patient burden rate of 80% according to the ‘Standards for Designation and Implementation of Selective Benefits’)</p> <p>2) If the patient is 18 years of age or older or after bone growth is completed</p> <p>3) Obesity that cannot be treated effectively with non-surgical treatment</p> <p>B. When restorative surgery is performed due to surgical complications or excess weight loss after obesity surgery</p> <p>C. When corrective surgery is performed due to surgical complications after obesity surgery, or when corrective surgery is performed despite active management for more than 18 months due to above A 1</p>	<p>1. If BMI is 35 kg/m<sup>2</sup> or higher If 6 months or more of internal medicine treatment is not sufficiently effective and in the presence of at least one complication of diabetes, hypertension, dyslipidemia, obstructive sleep apnea syndrome, or non-alcoholic fatty liver disease including non-alcoholic steatohepatitis</p> <p>2. If the BMI is 32–34.9 kg/m<sup>2</sup> If 6 months of medical treatment alone is not sufficiently effective and there are at least two of the following comorbidities: complications of diabetes, hypertension, dyslipidemia, obstructive sleep apnea syndrome, or non-alcoholic fatty liver disease including non-alcoholic steatohepatitis with HbA1c 8.0 or higher (NGSP value)</p>

BMI, body mass index; HbA1c, glycosylated hemoglobin; NGSP, National Glycohemoglobin Standardization Program.